Drugs / LY4066434
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06607185 | Oct 2024 → Jan 2030 expected | colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4066434 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06607185 ↗ |
| Action | Inhibit | “Pan-KRAS Inhibitor” NCT06607185 ↗ |
| Route | Oral | “Administered orally.” NCT06607185 ↗ |
| Target | KRAS | “A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors” NCT06607185 ↗ |